16 Jul 2026

CRC Research Update — July 16, 2026

Creator: The CRC Digest
Published: 2026-07-16T11:50:24Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

Fruquintinib plus PD-1 inhibitors in advanced CRC: real-world meta-analysis
A reconstructed patient-level meta-analysis examined survival outcomes for patients with advanced colorectal cancer treated with fruquintinib combined with PD-1 inhibitors after progression on standard chemotherapy. (BMC Cancer)
Emergency CRC diagnosis linked to worse outcomes and higher costs in older adults
Among 79,251 Medicare patients aged 65+ with colorectal cancer, those diagnosed via emergency presentation had worse clinical outcomes and higher healthcare costs compared to those diagnosed through screening or routine outpatient care. (J Surg Oncol)
Decision-tree model helps prioritize colonoscopy after positive screening test
Spanish researchers developed and validated a risk stratification tool using fecal hemoglobin concentration and clinical data to identify which patients with positive fecal immunochemical tests are at highest risk for colorectal cancer and should receive priority colonoscopy. (Dig Endosc)
CRC incidence after polypectomy tracked in UK Biobank cohort
UK Biobank data showed that during median 10-year follow-up after polypectomy, 78 incident colorectal cancers occurred (153 per 100,000 person-years). The study compared risk between the removal group and both the non-index-colonoscopy group and the polyp-free group using competing risk models. (Ann Gastroenterol)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Treatment variation impacts survival in early-onset metastatic CRC
A retrospective analysis of patients diagnosed with stage IV CRC between 2004-2022 found that treatment patterns and outcomes varied by age, with patients under 50 showing different utilization of chemotherapy, immunotherapy, and metastasis resection compared to older age groups. (J Surg Oncol)

🔎 Screening Watch

Screening guidelines, early detection, and prevention advances

Missed screening opportunities lead to emergency diagnosis and worse outcomes
SEER-Medicare analysis of older adults found that many CRC cases are diagnosed during emergency presentation, which are linked to worse outcomes compared to screening-detected cases. (J Surg Oncol)
New tool prioritizes colonoscopy for highest-risk patients
Decision-tree model using fecal hemoglobin and clinical data helps stratify CRC risk among those with positive fecal immunochemical tests, addressing colonoscopy capacity constraints. (Dig Endosc)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

Review examines immune checkpoint inhibitors in dMMR-MSI-H CRC
Comprehensive review discusses the immunological basis for exceptional responsiveness to PD-1 and CTLA-4 inhibitors in dMMR-MSI-H colorectal cancer, along with emerging resistance mechanisms and predictive biomarkers. (Front Immunol)
RAS mutation linked to early progression in liver metastases conversion therapy
Retrospective study of 194 patients with initially unresectable, pMMR colorectal liver metastases found that RAS mutation status was associated with early progression or recurrence after conversion therapy. (Front Surg)
Clinical complete response in MSS/KRAS-mutant mCRC with immunotherapy combination
Case report describes a 62-year-old woman with KRAS p.G12D, pMMR/MSS metastatic sigmoid colon cancer who achieved sustained regression with serplulimab, bevacizumab, and XELOX, with CEA declining from 3458.2 to 1812.84 ng/mL after two cycles. (Front Immunol)

Research continues to refine screening strategies, identify biomarkers that guide treatment, and explore new combinations for hard-to-treat subtypes.

Subscribe to The CRC Digest